Optiscan has been featured in Small Caps, highlighting the company’s lodgement of a US FDA 510(k) submission for its InVue precision surgery platform, following the recent submission of its InForm digital pathology device.

The article outlines how InVue is designed to bring real-time, cellular-level microscopic imaging directly into the operating theatre, enabling surgeons to visualise tissue while the patient remains in theatre. It highlights surgical oncology as a key initial market opportunity, with potential applications across breast, head and neck, colorectal, genitourinary, skin and other solid tumour procedures. The article also notes that FDA clearance would represent a critical step toward US commercialisation, while Optiscan continues to advance clinical reference sites, customer engagement, manufacturing scale-up and discussions with commercial partners.

CEO and Managing Director Dr. Camile Farah said: “It means we are now much closer to making a technology designed to give surgeons microscopic insight in real-time commercially available in the world’s most important healthcare markets.”

He added: “InVue potentially offers multiple advantages to surgeons and could change what they can see and when they can see it, providing them with a better course of action during surgery.”

Small Caps – Read the full article here.